AcrivaUD Trinova: creating better visual outcomes with a sinusoidal approach to trifocality
Not all multifocal IOLs are equal. A crucial part of the conversation between a patient who wants a multifocal IOL and the surgeon is finding out the patient’s ideal near and intermediate distances are – and then the multifocal IOL that would most closely match their preferences is selected. But the point is, vision isn’t just about near, intermediate and distance – it’s everything in between too.
Let’s examine conventional trifocal IOLs that achieve multifocality through multiple diffractive rings with sharp edges. The sharp edges enable diffraction – they abrupt change in the path of light, after all – but they also lead to unwanted light scattering, which patients typically experience as glare and halo. Further, this light dispersion leads to light loss of up to 15 percent, which decreases patients’ contrast sensitivity too. Then there’s the elephant in the room: these lenses might offer patients sharp near, intermediate and distance vision – but everything’s blurred in between.
The answer is VSY Biotechnology’s patent-pending Sinusoidal Seamless Vision Technology (SVT). Unlike traditional trifocals, the only SVT trifocal IOL, the Acriva Trinova has twelve unique sinusoidal stepless ridges. The smoothly varying surface profiles give rise not only to the highest levels of light transmission to the retina in the market (92 percent), but also optimum light distribution through all optical diameters. The result? Excellent modulation transfer function (MTF) at all distances, even in mesopic conditions, as well as excellent contrast sensitivity, reduced glare and halo, and outstanding dynamic visual performance – After all, the lens provides the widest depth of focus of all the currently available Trifocal IOLs thanks to its EDOF feature. Furthermore, SVT also allows the AcrivaUD Trinova to compensate for minor post-op refractive errors and slight tilts.
Ophthalmologists absolutely want to eliminate light loss (and the resulting loss in contrast sensitivity), glare, halo, and post-op refractive errors.
The Acriva Trinova lens has been commercially available since October 2017 and has been helping patients see better: near, intermediate and far – and everything in between, too.